In which country was Assimini developed? Drug background and manufacturer revealed

Asciminib is an innovative targeted therapy drug developed by the Swiss pharmaceutical company Novartis. As one of the world's leading pharmaceutical companies, Novartis has been committed to the research and development of innovative drugs in the fields of cancer, cardiovascular diseases, immune system diseases and other fields. As its latest research and development achievement in the field of hematological tumors, Aceminib is specifically used to treat patients with chronic myelogenous leukemia (CML), especially those who are resistant to traditional tyrosine kinase inhibitors (TKIs). Through a completely new mechanism, Aceminib offers new therapeutic hope to patients who do not benefit from traditional treatments.

The research and development background of Aceminib comes from the continuous optimization of the treatment effect of chronic myelogenous leukemia. CML is a blood cancer caused by the BCR-ABL1 fusion gene. For a long time, TKIs such as Imatinib have been the standard treatment for CML, significantly improving the survival rate of patients. However, as treatment progresses, some patients may develop resistance to these drugs, especially when the BCR-ABL1 gene has mutations (such as T315I mutation), which greatly reduces the efficacy of traditional TKIs. In response, Novartis began to develop a new targeted drug that could overcome these drug-resistant mutations, and Aceminib came into being.

Aximini is different from traditionalTKIs drugs. It does not work by directly inhibiting the kinase domain of BCR-ABL1, but by targeting a new binding site of the BCR-ABL1 protein-myristoyl pocket. This mechanism of action allows Asiminib to bypass some common TKIs resistance mutations, especially for those CML patients carrying the T315I mutation, which has a significant therapeutic effect. This innovative mode of action of aceminib makes it an important addition to the treatment of chronic myelogenous leukemia and provides a new option for patients in second- or third-line treatment.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib